P/E ratio for Alnylam Pharmaceuticals (ALNY)
P/E ratio as of June 2025 (TTM): -156
According to Alnylam Pharmaceuticals 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -155.903. At the end of 2023 the company had a P/E ratio of -54.2.
P/E ratio history for Alnylam Pharmaceuticals from 2004 to 2025
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2023 | -54.2 | 111.97% |
| 2022 | -25.6 | 8.61% |
| 2021 | -23.6 | 35.01% |
| 2020 | -17.4 | 23.3% |
| 2019 | -14.1 | 46.71% |
| 2018 | -9.64 | -58.93% |
| 2017 | -23.5 | 200.45% |
| 2016 | -7.82 | -71.36% |
| 2015 | -27.3 | 44.59% |
| 2014 | -18.9 | -58.03% |
| 2013 | -45.0 | 412.48% |
| 2012 | -8.77 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Arrowhead Pharmaceuticals
ARWR | -15.7 | -89.90% | 🇺🇸 USA |
 Regeneron Pharmaceuticals REGN | 12.6 | -108.08% | 🇺🇸 USA |
 Sarepta Therapeutics
SRPT | -14.4 | -90.74% | 🇺🇸 USA |
 OPKO Health
OPK | -26.9 | -82.75% | 🇺🇸 USA |
 Regulus Therapeutics RGLS | -11.1 | -92.90% | 🇺🇸 USA |
 Novartis NVS | 18.6 | -111.94% | 🇨🇭 Switzerland |
 Sanofi SNY | 17.5 | -111.24% | 🇫🇷 France |
 Teva Pharmaceutical Industries TEVA | -15.1 | -90.33% | 🇮🇱 Israel |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.